Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer with Primary Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Cohort Study
Oncology · 2025
DOI: 10.1159/000546834 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Oncology, 2025. Verfasst von Yonghong Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First People's Hospital of Tianmen, Tianmen, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Quinolines, Indoles, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
In this study, we aimed to evaluate the efficacy and safety of the combination therapy with chemotherapy and anlotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations who exhibit primary resistant to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).
Methods
Clinical data were collected from patients with advanced NSCLC harboring EGFR mutations and exhibiting primary resistance to EGFR-TKI, who were treated with a combination of chemotherapy and anlotinib. The primary endpoints were overall response rate (ORR), progression-free survival (PFS), disease control rate, overall survival (OS), and treatment-related adverse events (AEs).
Results
A total of 34 patients with advanced NSCLC harboring EGFR mutations and exhibiting primary resistance to EGFR-TKI were enrolled. The ORR and DCR for the treatment with chemotherapy plus anlotinib were 32.35% and 64.71%, respectively. The median PFS and OS were 5 months and 9 months, respectively. Compared to patients with EGFR exon 19 deletion mutations, those with EGFR exon 21 L858R mutations derived greater benefit from the treatment (mPFS = 4.0 months vs. 5.0 months, p < 0.05; mOS = 9.0 months vs. 10.0 months, p < 0.05). The common AEs were myelosuppression, hypertension, proteinuria, and hand-foot syndrome. Most AEs were mild and well tolerated. These findings suggest that chemotherapy combined with anlotinib may be a promising strategy to overcome primary resistance to EGFR-TKIs in patients with advanced NSCLC.
Conclusion
The combination of chemotherapy and anlotinib appears to be an effective and well-tolerated treatment strategy in patients with advanced NSCLC exhibiting primary resistance to EGFR-TKIs. Further studies are warranted to validate these findings and investigate long-term clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First People's Hospital of Tianmen, Tianmen, China.
- Department of Nursing, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Lymphoma, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, lixiaobing0629@126.com.
Zitieren
APA
Li, Y., Liu, Y., Peng, Y., Tang, J., & Li, X. (2025). Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer with Primary Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Cohort Study. Oncology. https://doi.org/10.1159/000546834
Vancouver
Li Y, Liu Y, Peng Y, Tang J, Li X. Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer with Primary Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Cohort Study. Oncology. 2025. doi:10.1159/000546834
BibTeX
@article{Li2025,
author = {Li, Yonghong and Liu, Yirui and Peng, Yi and Tang, Jing and Li, Xiaobing},
title = {Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer with Primary Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Cohort Study},
journal = {Oncology},
year = {2025},
doi = {10.1159/000546834}
}
EUVIMED